Pancreatic Cancer Research

ResearcherIowa City VA Medical CenterActive in the last 2 years

Joseph J. Cullen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2222-1328; OpenAlex author ID A5084443904; NIH RePORTER profile ID 1858439. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 2, last author 22)
Trials
3 (principal investigator on 2)
Grants
4
Labs led
2
Collaborators
39
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper, 1 trial · 2013: 3 papers, 1 grant · 2014: 1 paper, 1 trial · 2015: 3 papers · 2016: none · 2017: 2 papers · 2018: 4 papers, 1 trial, 2 grants · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers, 1 grant · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 29

  1. Pharmacologic ascorbate resistant pancreatic cancer demonstrates enhanced metastatic potential. Last author DOI 10.1016/j.redox.2025.103694↗
  2. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Last author DOI 10.1016/j.redox.2024.103375↗
  3. Pharmacologic Ascorbate Radiosensitizes Pancreatic Cancer but Radioprotects Normal Tissue: The Role of Oxidative Stress-Induced Lipid Peroxidation. Last author DOI 10.3390/antiox13030361↗
  4. Hydrogen Peroxide Mediates Pharmacological Ascorbate Induced Radio-Sensitization of Pancreatic Cancer Cells by Enhancing G2-accumulation and Reducing Cyclin B1… Last author DOI 10.1667/rade-22-00182.1↗
  5. Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer. Last author DOI 10.3390/antiox12091683↗
  6. Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002086↗
  7. Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer. Last author DOI 10.3390/antiox11050971↗
  8. Catalase Modulates the Radio-Sensitization of Pancreatic Cancer Cells by Pharmacological Ascorbate. Last author DOI 10.3390/antiox10040614↗
  9. Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism. Last author DOI 10.1038/s41598-020-74806-2↗
  10. Arachidonate 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid contribute to stromal aging-induced progression of pancreatic cancer. Co-author DOI 10.1074/jbc.ra120.012798↗
  11. Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage. Co-author DOI 10.1158/1541-7786.mcr-19-0381↗
  12. Enhanced Pharmacological Ascorbate Oxidation Radiosensitizes Pancreatic Cancer. Last author DOI 10.1667/rr15189.1↗
  13. Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma. Last author DOI 10.1007/s10585-018-9876-z↗
  14. Treating pancreatic cancer: more antioxidants more problems? First author DOI 10.1080/17474124.2018.1494572↗
  15. Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-18-1680↗
  16. A model for the detection of pancreatic ductal adenocarcinoma circulating tumor cells. Last author DOI 10.14440/jbm.2018.250↗
  17. Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer. Last author DOI 10.1002/mc.20199↗
  18. Superoxide Dismutases in Pancreatic Cancer. Last author DOI 10.3390/antiox6030066↗
  19. Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer. Last author DOI 10.1016/j.freeradbiomed.2015.02.018↗
  20. Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-14-1707↗
  21. Treatment of Pancreatic Cancer with Pharmacological Ascorbate. First author DOI 10.2174/138920101609150715135921↗
  22. Extracellular superoxide dismutase suppresses hypoxia-inducible factor-1α in pancreatic cancer. Last author DOI 10.1016/j.freeradbiomed.2014.02.002↗
  23. Regulation of pancreatic cancer growth by superoxide. Last author DOI 10.1002/mc.21891↗
  24. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Last author DOI 10.1007/s00280-013-2070-8↗
  25. Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Co-author DOI 10.1016/j.redox.2013.11.005↗
  26. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatoc… Last author DOI 10.1016/j.amjsurg.2012.07.007↗
  27. Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance. Co-author DOI 10.1016/j.freeradbiomed.2011.03.030↗
  28. Role of Rac1-dependent NADPH oxidase in the growth of pancreatic cancer. Last author DOI 10.1038/cgt.2010.64↗
  29. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Co-author DOI 10.1158/1541-7786.mcr-10-0475↗

Trials 3

  1. A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Study director NCT02905578↗
  2. Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I Principal investigator NCT01852890↗
  3. Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer Principal investigator NCT01515046↗

Grants 4

  1. Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer P01CA217797↗
  2. Mechanisms of pharmacological ascorbate inhibition of pancreatic cancer metastases I01BX001318↗
  3. Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer R01CA184051↗
  4. ASCORBATE-INDUCED RADIOSENSITIZATION IN PANCREATIC CANCER U01CA166800↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brianne R. O’Leary · 13 shared papers, 2018–2025 · strength 2.04
  2. Juan Du · 19 shared papers, 2013–2024 · strength 1.91
  3. Garry R. Buettner · 17 shared papers, 2011–2025 · strength 1.81
  4. Garett J. Steers · 5 shared papers, 2021–2024 · strength 0.92
  5. Matthew S. Alexander · 8 shared papers, 2017–2020 · strength 0.87
  6. Douglas Robert Spitz · 3 shared papers, 1 shared grant, 2011–2022 · strength 0.81
  7. Prabhat C. Goswami · 5 shared papers, 2014–2023 · strength 0.62
  8. Amanda N. Pope · 2 shared papers, 2023–2025 · strength 0.54
  9. Gloria Y. Chen · 2 shared papers, 2022–2024 · strength 0.43
  10. Justin G. Wilkes · 4 shared papers, 2017–2019 · strength 0.35
  11. Juan Du · 1 shared paper, 2025 · strength 0.30
  12. Kellie L. Bodeker · 4 shared papers, 2012–2024 · strength 0.30
  13. Bryan G. Allen · 3 shared papers, 2015–2024 · strength 0.27
  14. John Michael Buatti · 3 shared papers, 2012–2024 · strength 0.27
  15. Daniel Berg · 3 shared papers, 2013–2024 · strength 0.26
  16. John A. Cieslak · 4 shared papers, 2014–2015 · strength 0.23
  17. Ehab H. Sarsour · 2 shared papers, 2019–2020 · strength 0.21
  18. Naomi H. Fei · 1 shared paper, 2024 · strength 0.16
  19. Chandrikha Chandrasekharan · 1 shared paper, 2024 · strength 0.16
  20. Mandana Kamgar · 1 shared paper, 2024 · strength 0.16
  21. Joseph Michael Caster · 1 shared paper, 2024 · strength 0.16
  22. Zita A. Sibenaller · 3 shared papers, 2014–2018 · strength 0.16
  23. Ming‐Sound Tsao · 3 shared papers, 2011–2017 · strength 0.15
  24. Jessemae L. Welsh · 4 shared papers, 2012–2015 · strength 0.15
  25. Susan Tsai · 2 shared papers, 2015–2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.